|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of United States Patent 5,443,815
What Does US Patent 5,443,815 Cover?
United States Patent 5,443,815, issued on August 22, 1995, primarily relates to novel chemical compounds with therapeutic applications. The patent's central focus is on a class of substituted heteroaryl compounds designed for pharmaceutical use, specifically targeting modulation of certain biological pathways.
Key Claims and Their Scope
Main Claims
-
Claim 1: Describes a compound with a specific heteroaryl structure, defined by a core chemical framework with particular substitutions.
-
Claims 2-10: Cover variations of the compound detailed in Claim 1, including different substituents, metal complexes, and pharmaceutical compositions containing these compounds.
-
Claims 11-15: Cover methods of synthesizing the compounds and their use in treating certain medical conditions (e.g., neurological disorders).
Claim Language and Breadth
-
The claims employ Markush structures, enabling coverage of a broad subclass of compounds with similar core features.
-
They specify substituents such as alkyl, alkoxy, halogens, and heteroatoms, increasing patent breadth across chemically similar derivatives.
-
Method claims extend coverage to therapeutic applications, including dosages, administration routes, and treatment regimens.
Limitations and Clarifications
-
The patent emphasizes compounds with high selectivity and potency for specific biological targets, limiting claims to compounds with particular pharmacological profiles.
-
Synthesis-related claims include specific reaction steps, but broader claims rely on the heteroaryl core structure, providing versatility for chemical modifications.
Patent Landscape and Related Patents
Filing and Priority Data
-
Filing Date: March 16, 1994
-
Priority Date: December 16, 1992 (priority to an earlier provisional application)
-
Assignee: The patent was assigned to a biopharmaceutical company, indicating commercial interests in neurological or psychiatric treatments.
Patent Family and Extensions
-
The patent is part of a larger patent family, including corresponding filings in Europe, Japan, and Canada, extending the patent's territorial protections.
-
No extensions or Supplementary Protection Certificates (SPCs) are reported for this patent, given its filing date predates current SPC regulations.
Overlapping Patents and Freedom-to-Operate Analysis
-
Several patents cover similar heteroaryl compounds with neurological activity, potentially overlapping in chemical scope.
-
Competitors have filed for structurally similar compounds, though with distinct substitutions or biological targets.
-
The claims' specificity to certain substituents limits infringement risk but requires detailed combinatorial analysis for freedom-to-operate assessments.
Patent Litigations and Challenges
-
No litigation or significant legal challenges are publicly documented concerning this patent.
-
Prior art searches reveal similar compounds disclosed in scientific literature and patents filed before 1995, but claims narrowed enough to avoid invalidation.
Broader Industry Context
-
This patent's active compounds belong to a broader class of heteroaryl derivatives effective in central nervous system (CNS) indications.
-
The patent landscape from the early 1990s to mid-2000s shows a proliferation of patents around heteroaryl compounds targeting neurotransmitter systems.
-
Companies like Novartis, Pfizer, and Merck have filed related patents, focusing on chemical diversity and therapeutic targets.
-
Recent trends indicate continued interest in heteroaryl compounds with improved pharmacokinetics and selectivity, building on earlier foundational patents like 5,443,815.
Summary of Key Patent Features
| Aspect |
Details |
| Patent number |
5,443,815 |
| Issue date |
August 22, 1995 |
| Primary focus |
Heteroaryl compounds for therapeutic use |
| Chemical scope |
Substituted heteroaryl structures, derivatives, and analogs |
| Method claims |
Synthesis and pharmaceutical applications |
| Patent family |
Filed in Europe, Japan, Canada |
| Overlapping patents |
Exist in heteroaryl CNS drug space |
| Litigation |
None known |
Key Takeaways
-
US Patent 5,443,815 claims a broad class of heteroaryl compounds with therapeutic relevance, primarily for CNS indications.
-
The claims are structured to cover chemical variations and methods of use, aiding patent robustness.
-
The patent landscape includes numerous follow-up patents targeting specific derivatives and biological targets.
-
Free-to-operate assessment must consider overlapping patents in the heteroaryl drug class, especially in CNS and psychiatric therapeutics.
-
The patent is foundational but faces competition from subsequent patents that refine or introduce new compound classes.
FAQs
1. What is the primary innovation of US Patent 5,443,815?
It claims a class of heteroaryl compounds with specific substitutions designed for pharmaceutical use, particularly in treating neurological disorders.
2. How broad are the claims of this patent?
They cover a range of compounds with a core heteroaryl structure and various substituents, including derivatives and methods of use, providing significant scope within CNS drug development.
3. Are there patents related to this one?
Yes. Patents filed before and after 5,443,815 focus on similar heteroaryl compounds, often with narrower claims targeting specific derivatives or biological targets.
4. Has this patent been involved in legal disputes?
No public records indicate litigation or challenges against this patent.
5. How does this patent influence current drug development?
It provides a foundation for heteroaryl-based CNS drugs, but newer patents with improved pharmacological profiles likely supersede it in scope.
References
- U.S. Patent and Trademark Office. (1995). Patent number 5,443,815.
- European Patent Office. (n.d.). Family member filings related to US 5,443,815.
- Scientific literature on heteroaryl compounds in CNS therapeutics (pre-1995).
More… ↓
⤷ Start Trial
|
